In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea’s Ilyang Wins KFDA Approval For 2nd-Line Leukemia Drug Supect; Could Compete With Gleevec

This article was originally published in PharmAsia News

Executive Summary

Ilyang gears up to launch its chronic myeloid leukemia drug in Korea and other Asian markets for second-line treatment. The drug could eventually compete with Novartis AG's Gleevec (imatinib), which is approved for first-line treatment.

You may also be interested in...

Korea's Ilyang Pharmaceutical Starts Phase III Trials For First-line CML Drug To Compete With Gleevec

SEOUL - South Korea's Ilyang Pharmaceutical Co. Ltd. recently started Phase III trials for novel leukemia drug Supect (rodotinib) in Korea, India, Thailand, Philippines and Indonesia to determine whether it can gain approval in Korea as a first-line treatment for chronic myeloid leukemia and take on Novartis AG's Gleevec (imatinib). The company aspires to then bring the product to other Asian markets, and then eventually the U.S

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts